
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Chesapeake IRB, the technology-enabled independent institutional review board (IRB) serving the clinical research industry, announced its acquisition of Institutional Biosafety Corporation (IBC), a provider of institutional biosafety committee services located in Rockville, MD.
The acquisition now expands Chesapeake’s services with the ability to deliver comprehensive review and oversight of research using recombinant or synthetic DNA molecules, including clinical trials involving genetic engineering and gene therapy.






